From:  Behavioral and biochemical evaluation of the neuroprotective role of naringin in streptozotocin‑induced diabetic peripheral neuropathy in rats

 Effect of treatment on oxidative stress biomarkers in diabetic rats.

Brain content (mg pr)Groups
NCDCNGN-DGD-Dp-value
NO (μmol/L)5.47 ± 1.2319.18 ± 3.53a7.06 ± 2.62b7.97 ± 1.41bp < 0.01
MDA (nmol/mg pr)1.15 ± 0.295.42 ± 0.48a1.43 ± 0.31b1.81 ± 0.21bp < 0.01
GSH (μg/mg pr)7.17 ± 1.412.74 ± 0.12a6.14 ± 0.75b5.73 ± 1.06bp < 0.01
GPx (U/mg pr)28.14 ± 3.1916.21 ± 2.13a25.12 ± 3.41b24.28 ± 2.34bp < 0.01
SOD (units/mg pr) 5.41 ± 0.512.21 ± 1.48a4.72 ± 1.39b3.35 ± 1.15bp < 0.01
CAT (μmol of H2O2)5.53 ± 1.513.18 ± 0.46a5.62 ± 1.01b6.39 ± 1.33bp < 0.01

Data are expressed as means ± SEM of 10 rats/group. a Significantly different from the NC group (p < 0.01); b Significantly different from the DC group (p < 0.01). CAT: catalase; DC: diabetic control; GD-D: glimepiride-treated diabetic rats. GPx: glutathione peroxidase; GSH: reduced glutathione; MDA: malondialdehyde; NC: normal control; NGN-D: naringin-treated diabetic rats; NO: nitric oxide; SOD: superoxide dismutase.